{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:19:32Z","timestamp":1783937972498,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-026-03822-w","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:59:10Z","timestamp":1777640350000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["How can innovative trials in juvenile idiopathic arthritis serve the unmet needs of patients?"],"prefix":"10.1186","volume":"28","author":[{"given":"Joshua L","family":"Bennett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athimalaipet V.","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"6","key":"3822_CR1","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/rheumatology\/keab714","volume":"61","author":"R Costello","year":"2022","unstructured":"Costello R, McDonagh J, Hyrich KL, Humphreys JH. Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000\u20132018: results from the Clinical Practice Research Datalink. Rheumatology. 2022;61(6):2548\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/keab714.","journal-title":"Rheumatology"},{"key":"3822_CR2","doi-asserted-by":"publisher","unstructured":"Montserrat MA, Walig\u00f3ra J. The european union policy in the field of rare diseases. Public Health Genomics. 2013;16(6):268\u201377. https:\/\/doi.org\/10.1159\/000355930.","DOI":"10.1159\/000355930"},{"key":"3822_CR3","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. 2001. J Rheumatol. 2004;31(2):390. Available from: http:\/\/www.jrheum.org\/content\/31\/2\/390.abstract."},{"issue":"805","key":"3822_CR4","doi-asserted-by":"publisher","first-page":"eadt6050","DOI":"10.1126\/scitranslmed.adt6050","volume":"17","author":"C Bolton","year":"2025","unstructured":"Bolton C, Mahony CB, Clay E, Nisa PR, Lomholt S, Hackland A, et al. Synovial tissue atlas in juvenile idiopathic arthritis reveals pathogenic niches associated with disease severity. Sci Transl Med. 2025;17(805):eadt6050. https:\/\/doi.org\/10.1126\/scitranslmed.adt6050.","journal-title":"Sci Transl Med"},{"key":"3822_CR5","unstructured":"Angeles-Han ST, Srivastava SK. Screening, monitoring, and treating children with juvenile idiopathic arthritis\u2013associated uveitis: visualizing better outcomes. J Rheumatol. 2023;50(3):300. Available from: http:\/\/www.jrheum.org\/content\/50\/3\/300.abstract."},{"key":"3822_CR6","doi-asserted-by":"crossref","unstructured":"Oliveira Ramos F, Zinterl C, Fonseca JE. A lifelong journey: long-term perspectives on juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2024;38(3):101984. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S152169422400055X.","DOI":"10.1016\/j.berh.2024.101984"},{"issue":"4","key":"3822_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/acr.23853","volume":"72","author":"M Glerup","year":"2020","unstructured":"Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res (Hoboken). 2020;72(4):507\u201316. https:\/\/doi.org\/10.1002\/acr.23853.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"3822_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40272-024-00643-9","volume":"26","author":"C Wibrand","year":"2024","unstructured":"Wibrand C, Kyvsgaard N, Herlin T, Glerup M. Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management. Pediatr Drugs. 2024;26(5):479\u201398. https:\/\/doi.org\/10.1007\/s40272-024-00643-9.","journal-title":"Pediatr Drugs"},{"key":"3822_CR9","doi-asserted-by":"crossref","unstructured":"Feilding FL, Crosby L, Earle E, Beesley R, Leslie K, MacDonald E et al. How can trial designs better serve the needs of children and young people with juvenile idiopathic arthritis? Lancet Rheumatol. 2024;6(9):e648\u201352. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2665991324000262.","DOI":"10.1016\/S2665-9913(24)00026-2"},{"key":"3822_CR10","doi-asserted-by":"publisher","unstructured":"Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST et al. 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 2022;74(4):553\u2013569. https:\/\/doi.org\/10.1002\/art.42037.","DOI":"10.1002\/art.42037"},{"key":"3822_CR11","unstructured":"Fautrel B, Mitrovic S, De Matteis A, Bindoli S, Ant\u00f3n J, Belot A et al. EULAR\/PReS recommendations for the diagnosis and management of Still\u2019s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still\u2019s disease. Ann Rheum Dis. 2024;83(12):1614\u201327. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0003496724665635."},{"key":"3822_CR12","doi-asserted-by":"publisher","unstructured":"Balevic SJ, Becker ML, Cohen-Wolkowiez M, Schanberg LE. Clinical trial design in juvenile idiopathic arthritis. Pediatr Drugs. 2017;19(5):379\u2013389. https:\/\/doi.org\/10.1007\/s40272-017-0244-2.","DOI":"10.1007\/s40272-017-0244-2"},{"key":"3822_CR13","doi-asserted-by":"publisher","unstructured":"Berard RA, Laxer RM. Learning the hard way: clinical trials in juvenile idiopathic arthritis. Ann Rheum Dis. 2018;77(1):1\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211108.","DOI":"10.1136\/annrheumdis-2017-211108"},{"key":"3822_CR14","doi-asserted-by":"publisher","unstructured":"Lehman TJA. The future of pediatric rheumatology: Many questions remain. Arthritis and Rheumatism. 2007;56(9):2815\u20136. https:\/\/doi.org\/10.1002\/art.22837.","DOI":"10.1002\/art.22837"},{"key":"3822_CR15","doi-asserted-by":"publisher","unstructured":"Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9(9):557\u201363. https:\/\/doi.org\/10.1038\/nrrheum.2013.105.","DOI":"10.1038\/nrrheum.2013.105"},{"key":"3822_CR16","doi-asserted-by":"publisher","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385\u201395. https:\/\/doi.org\/10.1056\/NEJMoa1112802.","DOI":"10.1056\/NEJMoa1112802"},{"key":"3822_CR17","unstructured":"Giannini EH, Lovell DJ, Silverman ED, Sundel RP, Tague BL, Ruperto N. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I\/II study. J Rheumatol. 1996;23(5):919\u201324."},{"key":"3822_CR18","doi-asserted-by":"crossref","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342(11):763\u20139. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJM200003163421103.","DOI":"10.1056\/NEJM200003163421103"},{"key":"3822_CR19","doi-asserted-by":"publisher","unstructured":"Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Ann Rheum Dis. 2018;77(1):21\u201329. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210456.","DOI":"10.1136\/annrheumdis-2016-210456"},{"key":"3822_CR20","doi-asserted-by":"publisher","unstructured":"Ilowite NT, Prather K, Lokhnygina Y, Schanberg LE, Elder M, Milojevic D et al. The Randomized Placebo Phase Study Of Rilonacept in the Treatment of systemic juvenile idiopathic arthritis (RAPPORT). Arthritis Rheumatol. 2014;66(9) :2570\u20139. https:\/\/doi.org\/10.1002\/art.38699.","DOI":"10.1002\/art.38699"},{"key":"3822_CR21","doi-asserted-by":"crossref","unstructured":"Ramanan AV, Wason JMS. Adaptive and innovative study design in rare diseases. Arch Dis Child. 2025;110(1):1. Available from: http:\/\/adc.bmj.com\/content\/110\/1\/1.abstract.","DOI":"10.1136\/archdischild-2024-327143"},{"key":"3822_CR22","doi-asserted-by":"publisher","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16:29. https:\/\/doi.org\/10.1186\/s12916-018-1017-7.","DOI":"10.1186\/s12916-018-1017-7"},{"key":"3822_CR23","doi-asserted-by":"crossref","unstructured":"Ramanan A, Ruperto N, Foeldvari I, Vega Cornejo G, Keller S, Wang R et al. Efficacy and safety of ixekizumab in children with active juvenile psoriatic arthritis and enthesitis related arthritis (COSPIRIT-JIA): 16-week results of a multicentre, randomised, open-label study. In: ACR Convergence. 2024;76(suppl 9) https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-ixekizumab-in-children-with-active-juvenile-psoriatic-arthritis-and-enthesitis-related-arthritis-cospirit-jia-16-week-results-of-a-multicentre-randomised-open-label-study\/","DOI":"10.1136\/annrheumdis-2024-eular.LBA74"},{"issue":"1","key":"3822_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12969-025-01107-1","volume":"23","author":"AV Ramanan","year":"2025","unstructured":"Ramanan AV, Dick AD, Jaki T, Caruso G, Robertson DS, Jones AP, et al. Bayesian trial of adalimumab versus secukinumab for children with juvenile idiopathic arthritis associated uveitis or chronic anterior uveitis. Pediatr Rheumatol. 2025;23(1):55. https:\/\/doi.org\/10.1186\/s12969-025-01107-1.","journal-title":"Pediatr Rheumatol"},{"key":"3822_CR25","doi-asserted-by":"crossref","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1) :1-10.","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"3822_CR26","doi-asserted-by":"publisher","unstructured":"Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials. 2021;22(1):689. https:\/\/doi.org\/10.1186\/s13063-021-05651-5.","DOI":"10.1186\/s13063-021-05651-5"},{"issue":"4","key":"3822_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s43441-024-00656-z","volume":"58","author":"Y Li","year":"2024","unstructured":"Li Y, Nelson R, Izem R, Broglio K, Mundayat R, Gamalo M, et al. Unlocking the Potential: A Systematic Review of Master Protocol in Pediatrics. Ther Innov Regul Sci. 2024;58(4):634\u201344. https:\/\/doi.org\/10.1007\/s43441-024-00656-z.","journal-title":"Ther Innov Regul Sci"},{"key":"3822_CR28","doi-asserted-by":"publisher","unstructured":"Fisher BA, van de Wiel J, Turner JD, Liu YS, Hosack T, Young J, Ulcerative colitis and sjogren\u2019s disease (Paris). Pharmacodynamic activity of JNJ-67484703 in rheumatoid arthritis, : results of a phase II proof of biology trial. Ann Rheum Dis. 2025;84:389\u201390. https:\/\/doi.org\/10.1016\/j.ard.2025.05.482.","DOI":"10.1016\/j.ard.2025.05.482"},{"issue":"2","key":"3822_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/23971983241278079","volume":"10","author":"E Khanna Dinesh","year":"2024","unstructured":"Khanna Dinesh E, Luke B, Assassi Shervin B, Wade W, Gordon Gregory M, Karina, et al. Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease. J Scleroderma Relat Disord. 2024;10(2):121\u201332. https:\/\/doi.org\/10.1177\/23971983241278079.","journal-title":"J Scleroderma Relat Disord"},{"issue":"68","key":"3822_CR30","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jncimonographs\/lgae046","volume":"2025","author":"MM Nu\u00f1o","year":"2025","unstructured":"Nu\u00f1o MM, Pugh SL, Ji L, Piao J, Dignam JJ, Steingrimsson JA. On the use of external controls in clinical trials. JNCI Monogr. 2025;2025(68):30\u20134. https:\/\/doi.org\/10.1093\/jncimonographs\/lgae046.","journal-title":"JNCI Monogr"},{"key":"3822_CR31","doi-asserted-by":"crossref","unstructured":"Zayadi A, Edge R, Parker CE, Macdonald JK, Neustifter B, Chang J et al. Use of external control arms in immune-mediated inflammatory diseases: a systematic review. BMJ Open. 2023;13(12):e076677. Available from: http:\/\/bmjopen.bmj.com\/content\/13\/12\/e076677.abstract.","DOI":"10.1136\/bmjopen-2023-076677"},{"key":"3822_CR32","doi-asserted-by":"crossref","unstructured":"Horneff G, Burgos-Vargas R, Constantin T, Foeldvari I, Vojinovic J, Chasnyk VG et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73(6):1114\u201322. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0003496724149175.","DOI":"10.1136\/annrheumdis-2012-203046"},{"issue":"6","key":"3822_CR33","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/cpt.3441","volume":"116","author":"Y Qian","year":"2024","unstructured":"Qian Y, Schlachter L, Eckert D, Stodtmann S, Shmagel A, Peng Y, et al. Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure\u2013Response Models, and Real-World Patient Data. Clin Pharmacol Ther. 2024;116(6):1635\u201345. https:\/\/doi.org\/10.1002\/cpt.3441.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3822_CR34","doi-asserted-by":"publisher","first-page":"e11788","DOI":"10.1002\/acr2.11788","volume":"7","author":"Y Li","year":"2025","unstructured":"Li Y, Huang B, Andorf S, Yue X, Lovell DJ, Brunner HI. Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials. ACR Open Rheumatol. 2025;7(2):e11788. https:\/\/doi.org\/10.1002\/acr2.11788.","journal-title":"ACR Open Rheumatol"},{"key":"3822_CR35","doi-asserted-by":"publisher","unstructured":"Lawson-Tovey S, Smith SL, Geifman N, Shoop-Worrall S, Ng S, Barnes MR et al. The successes and challenges of harmonising Juvenile Idiopathic Arthritis (JIA) datasets to create a large-scale JIA data resource. Pediatr Rheumatol. 2023;21(1):70. https:\/\/doi.org\/10.1186\/s12969-023-00839-2.","DOI":"10.1186\/s12969-023-00839-2"},{"issue":"1","key":"3822_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-018-1780-z","volume":"20","author":"J Swart","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva \u0415, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20(1):285. https:\/\/doi.org\/10.1186\/s13075-018-1780-z.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3822_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/rheumatology\/kez214","volume":"59","author":"F McErlane","year":"2020","unstructured":"McErlane F, Armitt G, Cobb J, Bailey K, Cleary G, Douglas S, et al. CAPTURE-JIA: a consensus-derived core dataset to improve clinical care for children and young people with juvenile idiopathic arthritis. Rheumatology. 2020;59(1):137\u201345. https:\/\/doi.org\/10.1093\/rheumatology\/kez214.","journal-title":"Rheumatology"},{"key":"3822_CR38","doi-asserted-by":"publisher","unstructured":"Duurland CL, Wedderburn LR. Current developments in the use of biomarkers for juvenile idiopathic arthritis. Curr Rheumatol Rep. 2014;16(3):406. https:\/\/doi.org\/10.1007\/s11926-013-0406-3.","DOI":"10.1007\/s11926-013-0406-3"},{"key":"3822_CR39","doi-asserted-by":"publisher","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u2013269. https:\/\/doi.org\/10.1038\/s41584-021-00590-6.","DOI":"10.1038\/s41584-021-00590-6"},{"key":"3822_CR40","unstructured":"Pavlenko M, Altaye M, Brunner H, Chang M, Cooper A, Davidson S et al. Predicting JIA-associated uveitis using tear fluid biomarkers: a prospective multicenter study [abstract]. Arthritis Rheumatol. 2025;77((suppl 9)). https:\/\/acrabstracts.org\/abstract\/predicting-jia-associated-uveitis-using-tear-fluid-biomarkers-a-prospective-multicenter-study\/"},{"issue":"13","key":"3822_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/iovs.65.13.29","volume":"65","author":"L Rodr\u00edguez-Mart\u00ednez","year":"2024","unstructured":"Rodr\u00edguez-Mart\u00ednez L, Rodr\u00edguez-Fern\u00e1ndez CA, Rodr\u00edguez Lemos O, de Domingo B, Garc\u00eda Bru P, Mateos J, et al. Potential Prognostic Protein Biomarkers in Tears From Noninfectious Uveitis Patients Under Biologic Treatment as a Prelude to Personalized Medicine. Invest Ophthalmol Vis Sci. 2024;65(13):29. https:\/\/doi.org\/10.1167\/iovs.65.13.29.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"3822_CR42","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00417-020-04707-7","volume":"258","author":"IV Shirinsky","year":"2020","unstructured":"Shirinsky IV, Biryukova AA, Kalinovskaya NY, Shirinsky VS. Tear cytokines as potential biomarkers in non-infectious uveitis: post hoc analysis of a randomised clinical trial. Graefe\u2019s Archive Clin Experimental Ophthalmol. 2020;258(8):1813\u20139. https:\/\/doi.org\/10.1007\/s00417-020-04707-7.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol"},{"issue":"10271","key":"3822_CR43","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","volume":"397","author":"F Humby","year":"2021","unstructured":"Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, et al. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet. 2021;397(10271):305\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(20)32341-2.","journal-title":"Lancet"},{"issue":"11","key":"3822_CR44","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","volume":"5","author":"F Rivellese","year":"2023","unstructured":"Rivellese F, Nerviani A, Giorli G, Warren L, Jaworska E, Bombardieri M, et al. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol. 2023;5(11):e648\u201359. https:\/\/doi.org\/10.1016\/S2665-9913(23)00241-2.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"3822_CR45","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1038\/s41467-025-60987-9","volume":"16","author":"MJ Lewis","year":"2025","unstructured":"Lewis MJ, \u00c7ubuk C, Surace AEA, Sciacca E, Lau R, Goldmann K, et al. Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis. Nat Commun. 2025;16(1):5374. https:\/\/doi.org\/10.1038\/s41467-025-60987-9.","journal-title":"Nat Commun"},{"issue":"5","key":"3822_CR46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/cpt.1886","volume":"108","author":"I Tanaudommongkon","year":"2020","unstructured":"Tanaudommongkon I, John Miyagi S, Green DJ, Burnham JM, van den Anker JN, Park K, et al. Combined Pediatric and Adult Trials Submitted to the US Food and Drug Administration 2012\u20132018. Clin Pharmacol Ther. 2020;108(5):1018\u201325. https:\/\/doi.org\/10.1002\/cpt.1886.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03822-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:59:15Z","timestamp":1777640355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03822-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3822"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03822-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"7 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JLB\u2019s PhD was partially funded by an investigator-initiated research award from Pfizer; this funding was also used for conference attendance support. AVR has received Speaker fees\/Honoraria\/Consultancy from Abbvie, Eli Lilly, Novartis, Roche, UCB and SOBI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}